Novartis to Acquire Tourmaline Bio, Boosting Cardiovascular Pipeline with Pacibekitug for ASCVD…
Novartis announced it has agreed to acquire Tourmaline Bio, a clinical-stage biopharmaceutical company focused on developing pacibekitug, an anti-IL-6 monoclonal antibody designed to…
Read More...
Read More...
